Silvercrest Asset Management Group LLC increased its holdings in shares of Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 77.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 742,914 shares of the company's stock after purchasing an additional 323,216 shares during the period. Silvercrest Asset Management Group LLC owned 1.50% of Cryoport worth $5,780,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently modified their holdings of CYRX. Point72 Asia Singapore Pte. Ltd. boosted its stake in shares of Cryoport by 148.7% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock valued at $28,000 after purchasing an additional 2,120 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in Cryoport in the fourth quarter valued at approximately $51,000. Avanza Fonder AB acquired a new stake in Cryoport in the fourth quarter valued at approximately $64,000. Quarry LP acquired a new stake in Cryoport in the fourth quarter valued at approximately $69,000. Finally, ProShare Advisors LLC acquired a new stake in Cryoport in the fourth quarter valued at approximately $95,000. 92.90% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several brokerages have weighed in on CYRX. Needham & Company LLC restated a "buy" rating and issued a $11.00 target price on shares of Cryoport in a research note on Thursday, May 8th. Morgan Stanley lowered their target price on shares of Cryoport from $8.00 to $7.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Guggenheim restated a "buy" rating and issued a $10.00 target price on shares of Cryoport in a research note on Wednesday, April 16th. Roth Mkm restated a "buy" rating and issued a $15.00 target price on shares of Cryoport in a research note on Tuesday, April 1st. Finally, UBS Group raised their target price on shares of Cryoport from $10.00 to $11.00 and gave the company a "buy" rating in a research note on Tuesday, April 1st. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $11.00.
Get Our Latest Research Report on CYRX
Insiders Place Their Bets
In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $6.29, for a total value of $29,059.80. Following the completion of the transaction, the chief executive officer now owns 765,399 shares of the company's stock, valued at approximately $4,814,359.71. This trade represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last quarter, insiders sold 19,830 shares of company stock valued at $118,353. Insiders own 10.00% of the company's stock.
Cryoport Stock Performance
Shares of NASDAQ CYRX traded down $0.18 during midday trading on Friday, reaching $6.04. The company had a trading volume of 253,099 shares, compared to its average volume of 544,154. The business's 50-day simple moving average is $5.93 and its 200 day simple moving average is $6.82. The stock has a market cap of $302.83 million, a P/E ratio of -1.79 and a beta of 1.92. Cryoport, Inc. has a 1 year low of $4.58 and a 1 year high of $11.64. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48.
Cryoport (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. The business had revenue of $41.04 million during the quarter, compared to analysts' expectations of $56.19 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. On average, analysts forecast that Cryoport, Inc. will post -0.99 earnings per share for the current fiscal year.
About Cryoport
(
Free Report)
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Read More
Before you consider Cryoport, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cryoport wasn't on the list.
While Cryoport currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
